Showing results (21-30 of 720) with videos related to

Sort By:
Pageof 72
The Lancet. Haematology|May 4, 2020
Patients with haematological malignancies should not have to choose between transfusions and hospice careOreofe O Odejide, David P Steensma
The Lancet. Haematology|August 29, 2025
Estimated unit costs of anaemia interventions for women of reproductive age in 193 UN member states: a costing studyVictoria L Oliver, Yingying Wang, Sumie Leung, et al.
The Lancet. Haematology|August 7, 2021
Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trialFrederikus A Klok, Gerrit Toenges, Anna C Mavromanoli, et al.
The Lancet. Haematology|November 18, 2022
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm studyMazyar Shadman, Ian W Flinn, Moshe Y Levy, et al.
The Lancet. Haematology|October 19, 2016
Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trialJesús F San-Miguel, Vania T M Hungria, Sung-Soo Yoon, et al.
The Lancet. Haematology|April 9, 2017
Emergency transfusion of patients with unknown blood type with blood group O Rhesus D positive red blood cell concentrates: a prospective, single-centre, observational studyKathleen Selleng, Gregor Jenichen, Kathrin Denker, et al.
The Lancet. Haematology|February 22, 2017
Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trialJan Beyer-Westendorf, Sebastian M Schellong, Horst Gerlach, et al.
The Lancet. Haematology|February 22, 2017
Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trialAndrés J M Ferreri, Marianna Sassone, Francesco Zaja, et al.
The Lancet. Haematology|January 17, 2017
Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trialPreetesh Jain, Michael Keating, Sarah Renner, et al.
The Lancet. Haematology|October 9, 2022
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trialSagar Lonial, Rakesh Popat, Cyrille Hulin, et al.
Pageof 72